Patents Assigned to SORRISO PHARMACEUTICALS, INC.
  • Polynucleotides encoding, and method of making, a polypeptide comprising a VHH which binds interleukin-receptor (IL-7R)
    Patent number: 12247079
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: March 11, 2025
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Lurdes Duarte, Martyn Symmons, Keith Ray
  • Peptide construct having a protease-cleavable linker
    Patent number: 12234279
    Abstract: There is provided inter alia a construct suitable for oral administration comprising a first polypeptide and a second polypeptide connected by a labile peptide linker, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract and wherein the first and second polypeptides are substantially resistant to said one or more proteases.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: February 25, 2025
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts
  • Polypeptides
    Patent number: 12173054
    Abstract: Described herein is a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue. The polypeptides of this disclosure possess increased intestinal stability relative to a corresponding polypeptide not having the histidine substitutions.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: December 24, 2024
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton
  • Polypeptides comprising immunoglobulin chain variable domains which bind to interleukin-6 receptor (IL-6R) and methods of use thereof to treat autoimmune and inflammatory diseases
    Patent number: 12098197
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: September 24, 2024
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray
  • Compositions
    Patent number: 11684677
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-6R binding polypeptide.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: June 27, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Mike West, Keith Ray
  • VHH immunoglobulin chain variable domain that binds to IL-7R and methods of use thereof for treating autoimmune and/or inflammatory diseases
    Patent number: 11667719
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: June 6, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Lurdes Duarte, Martyn Symmons, Keith Ray
  • IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
    Patent number: 11623952
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: April 11, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Marion Cubitt, Tim Carlton, Luana Maggiore, Lurdes Duarte, Kevin Roberts, Mike West
  • Polypeptides which bind to interleukin-6 receptor (IL-6R)
    Patent number: 11401327
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: August 2, 2022
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray